Table 3: Univariate analysis of factors associated with “INF-γ” production.

ParameterAll patientsQuantiFERON-HCMV assayUnivariate
Reactive ( )Nonreactive ( )OR (95% CI) value

Post-SCT HCMV replication ( , (%))
  Yes13 (59.1)11 (84.6)2 (15.4)11 (1.4–85.2)0.026
  No9 (40.9)3 (33.3)6 (66.7)
Donor age ( , (%))
4012 (54.5)9 (75)3 (25)3 (0.5–16.2)0.378
40 10 (45.5)5 (50)5 (50)
Recipient age ( , (%))
  ≥4013 (59.1)11 (84.6)2 (15.4)11 (1.4–85.2)0.026
  <40 9 (40.9)3 (33.3)6 (66.7)
Donor HCMV serology ( , (%))
  Positive12 (54.5)10 (83.3)2 (16.7)7.5 (1–54.1)0.074
  Negative10 (45.5)4 (40)6 (60)
Recipient HCMV serology ( , (%))
  Positive19 (86.4)14 (73.7)5 (26.3)16.8 (0.8–418.6)0.089
  Negative3 (13.6)0 (0)a3 (100)
Stem cell source ( , (%))
  Peripheral blood11 (50)10 (90.9)1 (9.1)17.5 (1.6–191.9)0.024
  Bone marrow11 (50)4 (36.4)7 (63.6)

OR: odds ratio. CI: confidence interval. “Reactive” patients have an INF-γ production higher than 0.2 IU/mL. “Nonreactive” patients have less than 0.2 IU/mL. values < 0.05 were considered statistically significant.
aWe have added 0.5 to categories with 0 individuals using EPIDAT 3.1 software.